<DOC>
	<DOCNO>NCT00266695</DOCNO>
	<brief_summary>To provide ruboxistaurin treatment patient complete B7A-MC-MBCM study ( NCT00604383 ) , felt investigator potential benefit ruboxistaurin treatment . Patients must study drug 6 18 month completion B7A-MC-MBCM begin B7A-MC-MBDV . Additional data gather determine long-term safety effect ruboxistaurin vision .</brief_summary>
	<brief_title>Treatment Completers Study B7A-MC-MBCM</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>Patients complete Month 36 ( Visit 15 ) study B7AMCMBCM , investigator believe he/she would benefit ruboxistaurin treatment . Patients discontinue study B7AMCMBCM and/or investigator believe he/she would benefit ruboxistaurin treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>